Bram De Laere
Bram De Laere
Ghent University and Karolinska Institute
Geverifieerd e-mailadres voor - Homepage
Geciteerd door
Geciteerd door
Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells
W Onstenk, AM Sieuwerts, J Kraan, M Van, AJM Nieuweboer, ...
European urology 68 (6), 939-945, 2015
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
DJE Peeters, B De Laere, GG Van den Eynden, SJ Van Laere, F Rothé, ...
British journal of cancer 108 (6), 1358-1367, 2013
Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant …
B De Laere, PJ van Dam, T Whitington, M Mayrhofer, EH Diaz, ...
European urology 72 (2), 192-200, 2017
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer
B De Laere, S Oeyen, M Mayrhofer, T Whitington, PJ van Dam, ...
Clinical Cancer Research 25 (6), 1766-1773, 2019
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
A Brouwer, B De Laere, D Peeters, M Peeters, R Salgado, L Dirix, ...
Oncotarget 7 (30), 48625, 2016
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
M Mayrhofer, B De Laere, T Whitington, P Van Oyen, C Ghysel, J Ampe, ...
Genome medicine 10 (1), 1-13, 2018
Differential impact of RB status on E2F1 reprogramming in human cancer
C McNair, K Xu, AC Mandigo, M Benelli, B Leiby, D Rodrigues, J Lindberg, ...
The Journal of clinical investigation 128 (1), 341-358, 2018
Consensus statement on circulating biomarkers for advanced prostate cancer.
S Sumanasuriya, AG Omlin, AJ Armstrong, G Attard, KN Chi, CL Bevan, ...
Journal of Clinical Oncology 36 (6_suppl), 299-299, 2018
An in-depth evaluation of the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells
AM Sieuwerts, B Mostert, M van der Vlugt-Daane, J Kraan, CM Beaufort, ...
The Journal of Molecular Diagnostics 20 (3), 316-325, 2018
Circulating tumor cells and survival in abiraterone‐and enzalutamide‐treated patients with castration‐resistant prostate cancer
B De Laere, S Oeyen, P Van Oyen, C Ghysel, J Ampe, P Ost, W Demey, ...
The Prostate 78 (6), 435-445, 2018
Toward methodology for detection of cancer-promoting S100A4 protein conformations in subnanomolar concentrations using Raman and SERS
S Abdali, B De Laere, M Poulsen, M Grigorian, E Lukanidin, J Klingelhofer
The Journal of Physical Chemistry C 114 (16), 7274-7279, 2010
AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
AM Sieuwerts, W Onstenk, J Kraan, CM Beaufort, M Van, B De Laere, ...
Molecular oncology 13 (8), 1795-1807, 2019
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer
B De Laere, P Rajan, H Grönberg, L Dirix, J Lindberg
JAMA oncology 5 (7), 1060-1062, 2019
Has the prophecy of AR-V7 been fulfilled?
B De Laere, P Ost, H Gronberg, J Lindberg
Journal of Clinical Oncology 37 (24), 2181-2183, 2019
Exploring the intra-patient PIK3CA mutational heterogeneity of circulating tumour cells by massive parallel sequencing in patients with metastatic hormone receptor …
B De Laere, DJE Peeters, R Salgado, PB Vermeulen, PA van Dam, ...
Journal of Clinical Oncology 33 (15_suppl), 11030-11030, 2015
The ProBio Trial: Molecular Biomarkers for Advancing Personalized Treatment Decision in Patients with Metastatic Castration-Resistant Prostate Cancer
A Crippa, B De Laere, A Discacciati, B Larsson, JT Connor, EE Gabriel, ...
A multicenter project to test the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells
AM Sieuwerts, B Mostert, M van der Vlugt-Daane, J Kraan, C Beaufort, ...
Cancer Research 78 (13 Supplement), 2617-2617, 2018
EP-1597: Dose-escalation for early salvage radiotherapy in prostate cancer improves bDFS
E Latacz, P Dirix, B De Laere, P Van Dam, P Meijnders, P Huget, ...
Radiotherapy and Oncology 127, S859-S860, 2018
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
S Oeyen, V Liégeois, B De Laere, A Buys, M Strijbos, P Dirix, P Meijnders, ...
Prostate Cancer and Prostatic Diseases, 1-8, 2020
896TiP ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant …
J Lindberg, BD Laere, A Crippa, M Eklund, H Grönberg
Annals of Oncology 30 (Supplement_5), mdz248. 053, 2019
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20